A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

Abstract Background Prevention of unnecessary biopsies and overtreatment of indolent disease remains a challenge in the management of prostate cancer. Novel non-invasive tests that can identify clinically significant (intermediate-risk and high-risk) diseases are needed to improve risk stratificatio...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Fang Zhao, Ekaterina Olkhov-Mitsel, Shivani Kamdar, Renu Jeyapala, Julia Garcia, Rachel Hurst, Marcelino Yazbek Hanna, Robert Mills, Alexandra V. Tuzova, Eve O’Reilly, Sarah Kelly, Colin Cooper, The Movember Urine Biomarker Consortium, Daniel Brewer, Antoinette S. Perry, Jeremy Clark, Neil Fleshner, Bharati Bapat
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2018-11-01
סדרה:	Clinical Epigenetics
נושאים:	Prostate cancer PSA Urine DNA methylation Biomarker Early detection
גישה מקוונת:	http://link.springer.com/article/10.1186/s13148-018-0575-z
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!